Re:Ben Goldacre: Here’s the foreword to my new book, Bad Pharma
by mikeash on Tuesday September 25, 2012 @10:01AM
(#4570340)
Shouldn't other failed drugs count, though? If you have to develop e.g. five drugs for each one that you find to be successful, the R&D costs for the four that failed should be counted as part of the costs for the successful one.
[ Parent
| on HN ]
Re:Ben Goldacre: Here’s the foreword to my new book, Bad Pharma
by Alex3917 on Tuesday September 25, 2012 @10:24AM
(#4570471)
"Shouldn't other failed drugs count, though?"
Yes and no. Part of the issue is the pharma companies are only interested in testing new drugs that are under patent. Whereas these are by far the riskiest drugs to develop since much less is known about them. In contrast there are hundreds of other chemicals that have the potential to cure everything from cancer to PTSD, and they would cost only a few million dollars to turn into commercial drugs, but it's never done because there would be no profit in it. So yes failed drugs make sense to count from the viewpoint of the balance sheet of a pharma company, but it's not a very good answer to the question about how much it actually costs to develop an individual drug.
Re:Ben Goldacre: Here’s the foreword to my new book, Bad Pharma
by rchi on Tuesday September 25, 2012 @10:40AM
(#4570554)
I was taught it costs 100million dollars with one in ten chance of success
Re:Ben Goldacre: Here’s the foreword to my new book, Bad Pharma
by Alex3917 on Tuesday September 25, 2012 @10:49AM
(#4570619)
That's inherently wrong, if only because there's no one who knows the actual statistics. We know that it's possible to develop a drug for less than $20 million, how much pharma actually spends is indeterminate.